Drug Profile
Insulin inhalation - MAP Pharmaceuticals
Alternative Names: MAP 0001Latest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator MAP Pharmaceuticals
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 01 Mar 2013 MAP Pharmaceuticals has been acquired by Allergan
- 12 Mar 2009 MAP Pharmaceuticals does not plan to make further direct investment in MAP 0001 and is looking for partners to further develop the product (http://www.mappharma.com)